Westside Investment Management Inc. lessened its holdings in Pulse Biosciences, Inc. (NASDAQ:PLSE – Free Report) by 5.9% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 32,160 shares of the company’s stock after selling 2,015 shares during the period. Westside Investment Management Inc. owned 0.06% of Pulse Biosciences worth $280,000 as of its most recent SEC filing.
Separately, Griffin Asset Management Inc. boosted its holdings in shares of Pulse Biosciences by 15.7% during the 1st quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company’s stock valued at $2,616,000 after purchasing an additional 40,700 shares during the last quarter. 76.95% of the stock is owned by institutional investors.
Pulse Biosciences Price Performance
PLSE opened at $11.54 on Thursday. The firm has a 50-day simple moving average of $10.32 and a two-hundred day simple moving average of $9.58. Pulse Biosciences, Inc. has a 52 week low of $3.78 and a 52 week high of $14.96.
Analyst Upgrades and Downgrades
Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a report on Thursday, June 27th.
Get Our Latest Research Report on PLSE
Insiders Place Their Bets
In other news, CEO Burke Thomas Barrett acquired 10,000 shares of the firm’s stock in a transaction on Monday, May 20th. The stock was acquired at an average price of $8.56 per share, with a total value of $85,600.00. Following the completion of the purchase, the chief executive officer now directly owns 10,000 shares in the company, valued at $85,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 71.50% of the stock is owned by insiders.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Stories
- Five stocks we like better than Pulse Biosciences
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- What Are Dividend Challengers?
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Insider Trading – What You Need to Know
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Want to see what other hedge funds are holding PLSE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pulse Biosciences, Inc. (NASDAQ:PLSE – Free Report).
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.